Tyligand Bioscience Overview
- Year Founded
-
2018
- Status
-
IPO Registration
- Employees
-
64
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
14
Tyligand Bioscience General Information
Description
Developer and manufacturer of oral oncology drugs and antibody-drug conjugate platforms designed for KRAS-mutated and other solid tumors. The company provides clinical-stage drug candidates and a differentiated therapeutic pipeline, enabling cancer patients and healthcare providers with novel treatment mechanisms, improved survival outcomes, and solutions for unmet clinical needs.
Contact Information
Website
www.tyligand.com.cnCorporate Office
- West Building, Building 1
- No. 3728 Jinke Road, Pudong New Area
- Shanghai, 201203
- China
Corporate Office
- West Building, Building 1
- No. 3728 Jinke Road, Pudong New Area
- Shanghai, 201203
- China
Tyligand Bioscience Timeline
Tyligand Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. IPO | 29-Jan-2026 | Announced | Generating Revenue | |||
| 7. Later Stage VC (Series B) | 26-Jan-2026 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 08-Sep-2025 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 08-Jan-2025 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series A2) | 17-Apr-2024 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A1) | 28-Jun-2023 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 19-Apr-2021 | $20M | $28M | Completed | Clinical Trials - General | |
| 1. Early Stage VC | 10-Sep-2018 | $8.03M | $8.03M | Completed | Startup |
Tyligand Bioscience Patents
Tyligand Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026138732-A1 | Antibody-drug conjugate and use thereof | Pending | 24-Dec-2024 | ||
| WO-2026051996-A1 | Dual-payload antibody-drug conjugate and use thereof | Pending | 04-Sep-2024 | ||
| WO-2025214431-A1 | Hyaluronic acid cross-linked conjugate loaded with capsaicin | Pending | 11-Apr-2024 | ||
| AU-2025208223-A1 | Antibody-drug conjugate and use thereof | Pending | 08-Jan-2024 | ||
| WO-2025148868-A1 | Antibody-drug conjugate and use thereof | Inactive | 08-Jan-2024 | A61K47/6803 |
Tyligand Bioscience Signals
Tyligand Bioscience Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Tencent Holdings | Corporation | Minority | ||
| LAV (Lilly Asia Fund) | Corporate Venture Capital | Minority | ||
| Calor Capital | Venture Capital | Minority | ||
| Hangzhou Tailong Venture Capital Partnership | Growth/Expansion | Minority | ||
| Ming Bioventures | Venture Capital | Minority |
Tyligand Bioscience FAQs
-
When was Tyligand Bioscience founded?
Tyligand Bioscience was founded in 2018.
-
Where is Tyligand Bioscience headquartered?
Tyligand Bioscience is headquartered in Shanghai, China.
-
What is the size of Tyligand Bioscience?
Tyligand Bioscience has 64 total employees.
-
What industry is Tyligand Bioscience in?
Tyligand Bioscience’s primary industry is Drug Discovery.
-
Is Tyligand Bioscience a private or public company?
Tyligand Bioscience is a Private company.
-
What is Tyligand Bioscience’s current revenue?
The current revenue for Tyligand Bioscience is .
-
How much funding has Tyligand Bioscience raised over time?
Tyligand Bioscience has raised $111M.
-
Who are Tyligand Bioscience’s investors?
Tencent Holdings, LAV (Lilly Asia Fund), Calor Capital, Hangzhou Tailong Venture Capital Partnership, and Ming Bioventures are 5 of 14 investors who have invested in Tyligand Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process